Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines

Xenobiotica

Volumn 33, Issue 10, 2003, Pages 973-987

  Murray, M ^a   Murray, K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC AMINE; AMITRIPTYLINE; CYTOCHROME P450; CYTOCHROME P450 2C11; DESIPRAMINE; DICYCLOVERINE; DOXYLAMINE; DROFENINE; FLUOXETINE; IMIPRAMINE; N,N DIMETHYLDIPHENYLACETAMIDE; NAFTIDROFURYL; NISOXETINE; NORTRIPTYLINE; OXELADIN; PHENIRAMINE; PHENTOLOXAMINE; PROADIFEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEROTONIN UPTAKE INHIBITOR; TERTIARY AMINE; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; COMPLEX FORMATION; CONTROLLED STUDY; COVALENT BOND; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; LIVER METABOLISM; LIVER MICROSOME; MALE; NONHUMAN; OXIDATION; OXYGENATION; RAT; SPECTROSCOPY; STEROID HYDROXYLATION;

ADRENERGIC UPTAKE INHIBITORS; AMINES; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BINDING SITES; DESIPRAMINE; DIFFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLUOXETINE; HEME; HYDROXYLATION; INHIBITORY CONCENTRATION 50; KINETICS; LIVER; MALE; MICROSOMES, LIVER; MODELS, CHEMICAL; NADP; NORTRIPTYLINE; OXYGEN; PROTEIN BINDING; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; STEROID 16-ALPHA-HYDROXYLASE; STEROIDS; TIME FACTORS;

ANIMALIA;

EID: 0242351751     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250310001602748     Document Type: Article

References (42)

1. AVENOSO, A., SPINA, E., CAMPO, G., FACCIOLA, G., FERLITO, M., ZUCCARO, P., PERUCCA, E. and CAPUTI, A. P., 1997, Interaction between fluoxetine and haloperidol - pharmacokinetic and clinical implications. Pharmacological Research, 35, 335-339.
2. BAST, A. and NOORDHOEK, J., 1982, Spectral interaction of orphenadrine and its metabolites with oxidized and reduced hepatic microsomal cytochrome P-450 in the rat. Biochemical Pharmacology, 31, 2745-2753.
3. BAUMANN, P., 1996, Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clinical Pharmacokinetics, 31, 444-469.
4. BENSOUSSAN, C., DELAFORGE, M. and MANSUY, D., 1995, Particular ability of cytochromes CYP 3A to form inhibitory CYP-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochemical Pharmacology, 49, 591-602.
5. BERGSTROM, R. F., GOLDBERG, M. J., CERIMELE, B. J. and HATCHER, B. L., 1997, Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clinical Pharmacology and Therapeutics, 62, 643-651.
6. CACCIA, S., 1998, Metabolism of the newer antidepressants - an overview of the pharmacological and pharmacokinetic implications. Clinical Pharmacokinetics, 34, 281-302.
7. DANIEL, W. A., HADUCH, A. and WOJCIKOWSKI, J., 2002, Inhibition and possible induction of rat CYP2D after short-and long-term treatment with antidepressants. Journal of Pharmacy and Pharmacology, 54, 1545-1552.
8. DELAFORGE, M., JAOUEN, M. and MANSUY, D., 1983, Dual effects of macrolide antibiotics on rat liver cytochrome P-450. Induction and formation of metabolite-complexes: a structure-activity relationship. Biochemical Pharmacology, 32, 2309-2318.
9. FJORDSIDE, L., JEPPESEN, U., EAP, C. B., POWELL, K., BAUMANN, P. and BROSEN, K., 1999, The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics, 9, 55-60.
10. FRANKLIN, M. R., 1995, Enhanced rates of cytochrome P450 metabolic-intermediate complex formation from nonmacrolide amines in rifampicin-treated rabbit liver microsomes. Drug Metabolism and Disposition, 23, 1379-1382.
11. HANSCH, C., LEO, A., UNGER, S. H., KIM, H. K., NIKAITANI, D. and LIEN, E. J., 1973, 'Aromatic' substituent constants for structure-activity correlations. Journal of Medicinal Chemistry, 16, 1207-1216.
12. HANSCH, C., ROCKWELL, S. D., JOW, P. Y. C., LEO, A. and STELLER, E. E., 1977, Substituent constants for correlation analysis. Journal of Medicinal Chemistry, 20, 304-306.
13. HARVEY, A. T. and PRESKORN, S. H., 2001, Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. Journal of Clinical Psychopharmacology, 21, 161-166.
14. HEMERYCK, A., DE VRIENDT, C. and BELPAIRE, F. M., 1999, Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. European Journal of Clinical Pharmacology, 54, 947-951.
15. JEFCOATE, C. R., 1978, Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical difference spectroscopy. Methods in Enzymology, 52, 258-279.
16. JONSSON, K.-L. and LINDEKE, B., 1992, Cytochrome P-455 nm complex formation in the metabolism of phenylalkylamines. XII. Enantioselectivity and temperature dependence in microsomes and reconstituted cytochrome P-450 systems from rat liver. Chirality, 4, 469-477.
17. JONES, D. R., GORSKI, C. J. C., HAMMAN, M. A., MAYHEW, B. S., RIDER, S. and HALL, S. D., 1999, Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. Journal of Pharmacology and Experimental Therapeutics, 290, 1116-1125.
18. KOBAYASHI, K., YAMAMOTO, T., CHIBA, K., TANI, M., ISHIZAKI, T. and KUROIWA, Y., 1995, The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. British Journal of Clinical Pharmacology, 40, 481-485.
19. LINDEKE, B., PAULSEN, U. and ANDERSON, E., 1979, Cytochrome P-455 complex formation in the metabolism of phenylalkylamines - IV. Spectral evidences for metabolic conversion of methamphetamine to N-hydroxyamphetamine. Biochemical Pharmacology, 28, 3629-3635.
20. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
21. MANSUY, D., ROUER, E., BACOT, C., GANS, P., CHOTTARD, J. C. and LEROUX, J. P., 1978, Interaction of aliphatic N-hydroxylamines with microsomal cytochrome P450: nature of the different derived complexes and inhibitory effects on monoxygenases activities. Biochemical Pharmacology, 27, 1229-1237.
22. MARCUS, C. B., WILSON, N. M., JEFCOATE, C. R., WILKIKSON, C. F. and OMIECINSKI, C. J., 1990, Selective induction of cytochrome P450 isozymes in rat liver by 4-n-alkyl-methylenedioxybenzenes. Archives of Biochemistry and Biophysics, 277, 8-16.
23. MARTINI, R., BUTLER, A. M., JIANG, X.-M. and MURRAY, M., 1995, Pretranslational down regulation of cytochrome P450 2C11 in vitamin A-deficient male rat liver: Prevention by dietary inclusion of retinoic acid. Journal of Pharmacology and Experimental Therapeutics, 273, 427-434.
24. MAYHEW, B. S., JONES, D. R. and HALL, S. D., 2000, An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metabolism and Disposition, 28, 1031-1037.
25. MCNEIL, C. M. and MURRAY, M., 1996, Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites. Biochemical Pharmacology, 51, 15-20.
26. MURRAY, M., 1988, Complexation of cytochrome P450 isozymes in hepatic microsomes from SKF-525-A-induced rats. Archives of Biochemistry and Biophysics, 262, 381-388.
27. MURRAY, M., 1992, Metabolite intermediate complexation of microsomal cytochrome CYP 2C11 in male rat liver by nortriptyline. Molecular Pharmacology, 42, 931-938.
28. MURRAY, M. and FIELD, S. L., 1992, Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants. Biochemical Pharmacology, 43, 2065-2071.
29. MURRAY, M., SEFTON, R. M., MARTINI, R. and BUTLER, A. M., 1999, Comparative induction of CYP3A and CYP2B in rat liver by 3-benzoylpyridine and meyrapone. Chemico-Biological Interactions, 113, 161-173.
30. MURRAY, M., WILKINSON, C. F., MARCUS, C. and DUBE, C. E., 1983, Structure-activity relationships in the interactions of alkoxymethylenedioxybenzene derivatives with rat hepatic microsomal mixed-function oxidases in vivo. Molecular Pharmacology, 24, 129-136.
31. OMURA, T. and SATO, R., 1964, The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370-2378.
32. PERSHING, L. K. and FRANKLIN, M. R., 1982, Cytochrome P-450-metabolic-intermediate complex formation and induction by macrolide antibiotics: a new class of agents. Xenobiotica, 12, 687-699.
33. PESSAYRE, D., LARREY, D., VITAUX, J., BREIL, P., BELGHITI, J. and BENHAMOU, J.-P., 1982, Formation of an inactive cytochrome P-450 Fe (II)-metabolite complex after administration of troleandomycin in humans. Biochemical, Pharmacology, 31, 1699-1704.
34. REIDY, G. F., MEHTA, I. and MURRAY, M., 1989, Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Molecular Pharmacology, 35, 736-743.
35. REIN, H., RISTAU, O., MISSELWITZ, R., BUDER, E. and RUCKPAUL, K., 1979, The importance of the spin equilibrium in cytochrome P-450 for the reduction rate of the heme iron. Acta Biologica et Medica Germanica, 38, 187-199.
36. RING, B. J., BINKLEY, S. N., ROSKOS, L. and WRIGHTON, S. A., 1995, Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1′-hydroxy midazolam formation in vitro. Journal of Pharmacology and Experimental Therapeutics, 275, 1131-1135.
37. ROOS, P. H., 1999. Common multiple interactions of tricyclic antidepressants and orphenadrine with liver microsomal cytochrome P450 enzymes of the rat. Xenobiotica, 29, 629-640.
38. ROOS, P. H. and MAHNKE, A., 1996, Metabolite complex formation of orphenadrine with cytochrome P450. Biochemical Pharmacology, 52, 73-84.
39. SUTTON, D., BUTLER, A. M., NADIN, L. and MURRAY, M., 1997, Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites. Journal of Pharmacology and Experimental Therapeutics, 282, 294-300.
40. TRIEU, L. and MURRAY, M., 2000, Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem. Xenobiotica, 30, 131-140.
41. WAXMAN, D. J., KO, A. and WALSH, C., 1983, Regioselectivity and stereoselectivity of androgen hydroxylations catalysed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. Journal of Biological Chemistry, 258, 11937-11947.
42. YU, L.-S., WILKINSON, C. F. and ANDERS, M. W., 1980, Generation of carbon monoxide during the microsomal metabolism of methylenedioxyphenyl compounds. Biochemical Pharmacology, 29, 1113-1122.